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of terms for the ecologic description
of multihost systems. When we all
agree on what we are talking about,
we will understand each other better.
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Invasive
Mycobacterium
marinum Infections
To the Editor: Mycobacterium
marinum infections, commonly known
as fish tank granuloma, produce nodu-
lar or ulcerating skin lesions on the
extremities of healthy hosts. Delay of
diagnosis is common, and invasion
into deeper structures such as synovia,
bursae, and bone occurs in approxi-
mately one third of reported case-
patients (1).
A 49-year-old man with diabetes,
who had received a kidney transplant
from a living relative 8 years previ-
ously, sought treatment after 5 months
of worsening swelling and tenderness
of the left elbow. Of note, he had
injured his left ring finger while
cleaning barnacles from a piling 5
years previously and had contracted a
secondary infection that never com-
pletely healed despite three courses of
antimicrobial drugs and surgical
debridement. Physical examination
showed marked swelling, tenderness,
and warmth of the left elbow, as well
as of the left ring finger, which was
erythematous. Sterile aspiration of the
olecranon bursa showed 7,500 leuko-
cytes (62% lymphocytes) and 141,000
erythrocytes. Results of Gram stain
and routine cultures were negative.
Magnetic resonance imaging of the
left arm showed soft tissue edema of
the olecranon bursa and the left fourth
flexor digitorum longus tendon, and
no osteomyelitis. Three weeks later,
olecranon bursa aspirate fluid cultures
incubated on chocolate agar and 7H11
plates at 31°C, as well as on algae
slant, and mycobacterial growth indi-
cator tubes incubated at 37°C grew
M.ycobacterium marinum. The isolate
was susceptible to most agents but
showed intermediate susceptiblity to
ciprofloxacin (MIC 2 µg/mL) and was
resistant to ampicillin/clavulanate and
erythromycin (MIC 8 µg/mL and 32
µg/mL, respectively). A treatment
regimen of  rifampin and ethambutol
was begun, and the patient  showed a
dramatic improvement in the ensuing
several weeks. The patient has com-
pleted 9 of 11.4 planned months of
therapy and continues to do well, with
frequent office visits. 
Case reports from English lan-
guage MEDLINE articles since 1966
under the subject heading Mycobac-
terium marinum were cross-refer-
enced with articles containing the fol-
lowing text words: disseminated,
osteomyelitis, arthritis, synovitis, and
bursitis. Ten case reports were identi-
fied, and a hand search through perti-
nent articles’ references yielded 13
additional reports. A total of 35 cases
of invasive M. marinum disease were
then reviewed, according to patient
age and sex, symptoms, source of
infection, immune impairment, time
to diagnosis, and type as well as dura-
tion of therapy (2–24) (see online
Table at http://www.cdc.gov/ nci-
dod/EID/vol9no11/03-0192.htm#
table).
Most cases occurred in previously
healthy adults. The average age was
43 years; 24 (69%) were men; 21
(60%) had tenosynovitis; 6 (17%) had
septic arthritis; and 13 (37%) had
osteomyelitis. In three patients (9%),
either a bone marrow or blood culture
positive for M. marinum was
obtained; all three patients showed
marked systemic immunocompro-
mise. Multiple skin lesions were seen
in 23% of cases; half of these patients
showed clear evidence of deeper
infection. Some patients had more
than one manifestation of invasive
disease. Immunologic impairment
was a frequent component of invasive
M. marinum infections: 14 (40%) of
case-patients received a steroid injec-
tion at the site of infection, and 9
(26%) were receiving systemic
steroids for various indications. An
additional 4 (11%) case-patients were
in an immunocompromised state from
other sources such as chemotherapy
or AIDS. Delayed diagnosis was also
a prominent finding: The average time
to diagnosis was 17 months from
symptom onset. The treatment course
was prolonged and aggressive: The
average treatment duration was 11.4
months in the 20 reports in which a
definitive duration was given. Surgery
was undertaken in 69% of the cases.
The treatment regimen used varied
considerably, although 30 (88%) of
the 34 patients who took antimy-
cobacterial medications received
combination therapy. Rifampin (76%)
and ethambutol (68%) were the pre-
dominant agents. 
While M. marinum infections usu-
ally arise from aquatic trauma in
healthy hosts, delayed diagnosis and
immune suppression contribute to the
pathogenesis of invasive infection.
Tenosynovitis is the most common
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manifestation of deep invasion,
although septic arthritis and
osteomyelitis are well described.
Disseminated skin lesions can accom-
pany deeper invasion but may be seen
in isolation as well. Bone marrow
invasion and bacteremia are rare and
have been seen only in profoundly
immunocompromised patients. 
Although the rarity of the condi-
tion makes estimating its incidence
difficult, the number of case reports
per year has remained stable for the
last 30 years. However, the high fre-
quency of delayed diagnosis in cases
of invasive M. marinum disease
underscores the importance of main-
taining a high level of suspicion for
this condition, especially in patients
who have evidence of previous aquat-
ic trauma or refractory soft tissue
infections. Further, since immunosu-
pression was common in cases of
invasive disease, local steroid injec-
tions should be avoided in patients
with soft tissue infection after aquatic
trauma at least until M. marinum
infection is ruled out by acid-fast
staining or mycobacterial culture of
biopsy specimens or fluids. 
Once invasive M. marinum disease
was diagnosed, patients with invasive
disease were treated for an average of
11.4 months, three times longer than
the typical course for M. marinum
superficial infections (1). Rifampin
and ethambutol were used most often
in invasive infections, although many
therapeutic choices exist. In a study of
61 clinical isolates, rifamycins and
clarithromycin were the most potent,
with the lowest MICs, and resistance
was uncommon. Doxycycline, etham-
butol, and minocycline all showed
higher MICs but were still effective
(1). A different group tested 11 agents
against 37 clinical isolates and found
that trimethoprim/sulfamethoxazole
was the most potent agent, but 92% of
isolates were susceptible. Clarithro-
mycin and minocycline, by contrast,
showed susceptibility rates approach-
ing 100% and retained similar poten-
cy (25). This study reported an MIC50
for most quinolones of 4 µg/mL or
higher, although in a different study,
100% of M. marinum isolates were
susceptible to gatifloxacin (26).
Approximately three fourths of iso-
lates in this latter study were suscepti-
ble to ciprofloxacin and levofloxacin.
Among newer antibiotics tested
against M. marinum in this series,
only linezolid showed much promise
(26). On the basis of the sparse data
correlating susceptibility testing
results to clinical response, and the
relative infrequency of resistance,
recent guidelines suggest foregoing
susceptibility testing in M. marinum
infections unless the infection does
not respond to treatment (27). Most
cases of invasive M. marinum infec-
tion require surgical debridement,
69% in this series. This approach
seems particularly appropriate in
immunocompromised patients, those
with tenosynovitis, or those for whom
medical therapy fails. 
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Rickettsialpox in
Turkey
To the Editor: Rickettsialpox is
often described as a chickenpox-like
disease and is caused by Rickettsia
akari, a spotted fever group Rickettsia
that is transmitted to humans by the
bite of mites (Liponyssoides
sanguineus). Although the mite host
(typically a mouse) is widely
distributed in cities, the disease is
infrequently diagnosed. It is typically
characterized in patients by the
appearance of a primary eschar at the
site of a mite bite followed by fever,
headache, and development of a
papulovesicular rash. Symptoms
normally appear 9–14 days after the
mite bite and are often unnoticed by
the affected person. In documented
rickettsialpox cases, the presence of a
papule that ulcerates and becomes a
scar approximately 0.5–3.0 cm in
diameter is reported (1–3). Three to 7
days later, symptoms are more
pronounced, with patients
experiencing the sudden onset of
chills, fever, and headache followed
by myalgia and the appearence of
generalized vesicular skin rashes.
Less frequently, photophobia,
conjunctival injection, cough,
generalized lymphadenopathy, and
vomiting are reported.
The first well-described clinical
case of rickettsialpox was docu-
mented in New York City in 1946 (1).
Historically, most documented
rickettsialpox cases have occurred in
large metropolitan areas of the United
States (2), where the causative agent,
R. akari, circulates primarily between
the house mouse (Mus musculus) and
its mite (Liponyssoides sanguineus).
Recently, rickettsialpox cases have
been reported from Croatia, Ukraine,
South Africa, Korea, and North
Carolina (3,4). R. akari was isolated
from the blood of a patient suspected
of having Mediterranean spotted fever
rather than rickettsialpox; this was the
first human isolate of R. akari
reported in >40 years (4). Recent
reports of a rickettsialpox case in
North Carolina (3), R. akari
seropositivity found in HIV-positive
intravenous drug users in the inner
city of Baltimore, Maryland (5), and
in Central and East Harlem, New York
City (6), as well as rickettsialpox
cutaneous eruption in an HIV patient
in New York (7), indicate that R. akari
rickettsiosis is more common than
previously thought and presents the
risk of sporadic outbreaks worldwide.
We describe the clinical
presentation of rickettsialpox in a 9-
year-old boy from Nevpehir, located
in the middle region of Turkey.
Previously, a report from the Antalya
area of Turkey described the
prevalence of serum immunoglobulin
(Ig) G antibodies in humans directed
against R. conorii (spotted fever
group Rickettsia) (8); however,
rickettsialpox was not reported in
Turkey. This report of what we
believe to be the first described
rickettsialpox case from Turkey
further extends the recognized
geographic distribution of R. akari.
A 9-year-old boy was admitted to
the Kayseri hospital with fever >39°C
and generalized papulovesicular
exanthema. One week before
admission, fever, profuse sweating,
headache, and dysuria were present.
On admission, physical examination
indicated generalized vesicular,
bullouse, and papular exanthema
involving the lips and oral cavity.
Notable pathologic findings at
admission included a black eschar on
the boy’s penis, bilateral prominent
conjunctival ejection, and bilateral
lower pulmonary rales. The leukocyte
count was 13,300/mm3, hemoglobin
was 14.49 mg/dL, and the platelet
count was 544,000/mm3. Serum
electrolytes and blood urea nitrogen
levels and results of coagulation study
and urine analysis were normal.
Routine blood cultures taken 24 hours
postadmission were sterile. Specific
antibodies (IgG; IgM) against
Varicella were not detected in serum
samples (Duzen Laboratories,
Ankara, Turkey). Additionally, the
patient reported mice on the family’s
farm.
A diagnosis of rickettsialpox was
made and doxycycline treatment (200
mg/kg) was initiated. The patient
serum sample was tested by indirect
immunofluorescence assay (IFA) for
IgG and IgM antibodies reactive with
R. akari (Kaplan strain), R. typhi
(Wilmington), R. rickettsii (Sheila
Smith), and R. conorii (Malish 7).
Serum IgG titers of 1/1280 and IgM
of 1/40 to R. akari were detected and
confirmed through cross-adsorption
with rickettsial antigens (R. rickettsii,
